

This announcement replaces RNS No 2632M released on 26 April 2024 at 14:13 which misstated the Savills Deferred Share Bonus Plan grant allocations in respect of R Lee, D Lipson and C Mancini and consequently the resulting beneficial interests of those individuals, which should have been stated as follows:

PDMR	Number of shares subject to the Savills Deferred Share Bonus Plan awarded to the PDMR on 24 April 2024	Resulting beneficial interest under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan
Raymond Lee	19,704	150,278
David Lipson	4,859	148,948
Christian Mancini	10,537	148,971

All other details remain unchanged. The amended text of the full announcement of 26 April 2024 is shown below.

#### SAVILLS PLC (THE "COMPANY")

#### TRANSACTION IN SHARES BY DIRECTORS AND PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES (PDMRS)

##### Vesting of Share Awards

Awards over ordinary shares of the Company under the Deferred Share Plan have become unconditional in all respects following the end of their Deferred Period. In satisfaction of the Awards, the Trustee of the Savills US Employee Benefit Trust effected the transfer of shares, following the settlement of associated tax liabilities through the sale of shares, to a PDMR of the Company based in North America as follows:-

PDMR	Number of Shares Transferred	Number of Shares Disposed	Shareholding following this notification	
David Lipson	39,058	19,488	103,699	

The share price on disposal of shares was £10.45 per share.

##### Grant of Share Awards

The Company announces that on 24 April 2024 the grant of the share-based element of 2023 profit share awards has been made under the Savills Deferred Share Bonus Plan to Directors and PDMRs as follows:-

Director/ PDMR	Number of shares subject to the Savills Deferred Share Bonus Plan awarded to the Director/ PDMR on 24 April 2024
Mark Ridley (Director)	58,841
Simon Shaw (Director)	45,105
Alex Jeffrey (PDMR)	18,234
Chris Lee (PDMR)	9,596

Raymond Lee (PDMR)	19,704
David Lipson (PDMR)	4,859
Christian Mancini (PDMR)	10,537
James Sparrow (PDMR)	33,589

These awards have a Deferred Period of three years and are subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting date to reflect final and interim dividends declared during the Deferred Period.

The Company announces that on 24 April 2024 the grant of an award has been made under The Schedule to The Savills Deferred Share Plan to a PDMR based in the United States of America as follows:-

<b>PDMR</b>	<b>Number of shares subject to the Savills Deferred Share Plan awarded to the PDMR on 24 April 2024</b>
David Lipson (PDMR)	38,563

One-third of Mr Lipson's award will vest on each of the three anniversaries subsequent to the date of grant subject to continued employment and performance. The award is subject to rolled-up dividend shares whereby the number of shares awarded will be increased on the vesting dates to reflect final and interim dividends declared during the Deferred Periods.

Resulting beneficial interests under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan further to the above notifications are as follows:

<b>Director/ PDMR</b>	<b>Resulting beneficial interest under the Savills Deferred Share Bonus Plan and Savills Deferred Share Plan</b>
Mark Ridley (Director)	281,493
Simon Shaw (Director)	214,056
Alex Jeffrey (PDMR)	307,184
Chris Lee (PDMR)	74,917
Raymond Lee (PDMR)	150,278
David Lipson (PDMR)	148,948
Christian Mancini (PDMR)	148,971
James Sparrow (PDMR)	163,057

The information set out below is provided in accordance with the requirements of Article 19 of the EU Market Abuse Regulation No 596/2014.

<b>1.</b>	<b>Details of the Director/ PDMR</b>
-----------	--------------------------------------

(a)	Name	1. Mark Ridley 2. Simon Shaw 3. Alex Jeffrey 4. Chris Lee 5. Raymond Lee 6. David Lipson 7. Christian Mancini 8. James Sparrow	
2.	Reason for the notification		
(a)	Position/ status	1. Group Chief Executive/ Director 2. Group Chief Financial Officer/ Director 3. Chief Executive Officer - Savills Investment Management/ PDMR 4. Group Legal Director and Company Secretary/ PDMR 5. Chief Executive - Hong Kong, Macau and Greater China/ PDMR 6. Chief Executive Officer - Savills North America/ PDMR 7. Chief Executive Officer - Asia Pacific (ex- Greater China)/ PDMR 8. Chief Executive Officer, UK & CEME/ PDMR	
(b)	Initial notification/ Amendment	Initial notification	
3.	Details of the issuer		
(a)	Name	Savills plc	
(b)	LEI	213800WXICGMBWHTA933	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
(a)	Description of the Financial Instrument	Savills plc Ordinary Shares of 2.5p each	
(b)	Identification code of the Financial Instrument	GB00B135BJ46	
(c)	Nature of the transaction	1) Vesting of awards under the Company's Deferred Share Plan and sale of shares to satisfy associated tax liabilities 2) Grant of awards over Ordinary Shares in accordance with the Company's Deferred Share Bonus Plan and Deferred Share Plan	
(d)	Price(s) and volume(s)	Price(s)	Volume(s)
		1) Acquisition £nil per share   <	

		2) £nil per share	1. 58,541 2. 45,105 3. 18,234 4. 9,596 5. 19,704 6. 43,422 7. 10,537 8. 33,589
(e)	Aggregated information  - Aggregated volume - Price	N/A	
(f)	Date of the transaction	24 April 2024	
(g)	Place of the transaction	Outside a trading venue	

**Name of contact and telephone number for queries:**

Chris Lee

Group Legal Director & Company Secretary

020 3107 5444

4 June 2024



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHMZGGVFDVGDZM